Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology now and into the future.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives, while creating value for society. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
Twitter Feed
-
A tailored game plan starts with knowledge - click here to take the #AdvantageHers chronic inflammatory disease questionnaire and download helpful resources today! https://t.co/lTCXHtX4kv
— UCB News (@ucb_news) 22.09.2021 -
During #ITPAwarenessWeek, we are emphasizing our commitment to working with the patient and advocacy community to raise awareness of little understood conditions and support participation in ongoing research into rare diseases. #ITPStrongerTogether https:
— UCB News (@ucb_news) 22.09.2021 -
Our mission for the #ImmunologySummit2021 is to provide unparalleled learning experiences that inspire, challenge and support healthcare professionals to truly transform the lives of patients living with severe immunology diseases. https://t.co/vAvPCL2Nlr
— UCB News (@ucb_news) 22.09.2021
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
